TB-500 acts as a primary G-actin sequestering molecule in mammalian cells. By regulating actin polymerization, it facilitates rapid cell motility to sites of injury, promoting angiogenesis, dermal wound closure, and muscular tissue repair.
A synthetic version of the naturally occurring actin-sequestering protein Thymosin Beta-4, researched for cell migration and tissue regeneration.
~24 - 48 hours (systemic activity)
G-Actin Binding Domain
C212H350N56O78S
Investigated via subcutaneous and intramuscular injection.
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for TB-500: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C212H350N56O78S
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
TB-500 acts as a primary G-actin sequestering molecule in mammalian cells. By regulating actin polymerization, it facilitates rapid cell motility to sites of injury, promoting angiogenesis, dermal wound closure, and muscular tissue repair.
Binds monomeric actin to facilitate cytoskeletal remodeling, upregulates endothelial cell migration, and downregulates inflammatory cytokine cascades in damaged tissues.
Peer-reviewed publications, clinical trials, and preclinical research investigating TB-500.
Documented literature dosing intervals and published clinical trial protocols.
Biological delivery routes and standardized laboratory reconstitution principles.
Investigated via subcutaneous and intramuscular injection.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.